1. Home
  2. HUMA vs ALT Comparison

HUMA vs ALT Comparison

Compare HUMA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HUMA
  • ALT
  • Stock Information
  • Founded
  • HUMA 2004
  • ALT 1997
  • Country
  • HUMA United States
  • ALT United States
  • Employees
  • HUMA N/A
  • ALT N/A
  • Industry
  • HUMA Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • HUMA Health Care
  • ALT Health Care
  • Exchange
  • HUMA Nasdaq
  • ALT Nasdaq
  • Market Cap
  • HUMA 250.2M
  • ALT 292.0M
  • IPO Year
  • HUMA N/A
  • ALT N/A
  • Fundamental
  • Price
  • HUMA $1.51
  • ALT $3.83
  • Analyst Decision
  • HUMA Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • HUMA 8
  • ALT 6
  • Target Price
  • HUMA $10.88
  • ALT $17.40
  • AVG Volume (30 Days)
  • HUMA 5.9M
  • ALT 3.0M
  • Earning Date
  • HUMA 08-11-2025
  • ALT 08-12-2025
  • Dividend Yield
  • HUMA N/A
  • ALT N/A
  • EPS Growth
  • HUMA N/A
  • ALT N/A
  • EPS
  • HUMA N/A
  • ALT N/A
  • Revenue
  • HUMA $818,000.00
  • ALT $20,000.00
  • Revenue This Year
  • HUMA N/A
  • ALT N/A
  • Revenue Next Year
  • HUMA $949.92
  • ALT $761,880.20
  • P/E Ratio
  • HUMA N/A
  • ALT N/A
  • Revenue Growth
  • HUMA N/A
  • ALT N/A
  • 52 Week Low
  • HUMA $1.15
  • ALT $2.90
  • 52 Week High
  • HUMA $6.77
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • HUMA 36.87
  • ALT 51.79
  • Support Level
  • HUMA $1.43
  • ALT $3.35
  • Resistance Level
  • HUMA $1.67
  • ALT $3.66
  • Average True Range (ATR)
  • HUMA 0.15
  • ALT 0.19
  • MACD
  • HUMA -0.01
  • ALT 0.07
  • Stochastic Oscillator
  • HUMA 23.32
  • ALT 86.18

About HUMA Humacyte Inc.

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: